Paratek Pharmaceuticals Stock News

Paratek (PRTK) delivered earnings and revenue surprises of -31.03% and -3.94%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Shares of Paratek Pharmaceuticals (NASDAQ:PRTK) rose in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share increased 137.74% over the past year to $0.20,

-- NUZYRA® (omadacycline) Generated Net U.S. Sales of $14.9 Million from the Core Commercial Business, a 13% Increase over the Prior Quarter

The stock price of Paratek Pharmaceuticals Inc (NASDAQ: PRTK) increased by over 10% pre-market. This is why it happened.

The Center for Disease Control and Prevention (CDC) has added Paratek Pharmaceuticals Inc's (NASDAQ: PRTK) antibiotic Nuzyra (omadacycline) as an alternative agent for pre-exposure prophylaxis an

BOSTON, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-savi

BOSTON, Aug. 03, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-savi

BOSTON, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-savi

BOSTON, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-savi

Do you agree with analysts on these penny stocks? The post 9 Hot Penny Stocks To Watch Right Now, Analyst Targets Up To 290% appeared first on Penny Stocks to Buy, Picks, News and Information | PennyS

The company reduced its 2021 revenue outlook.

-- U.S.-Based Sites Ready to Begin Enrolling Patients, Placebo-Controlled Study Evaluating NUZYRA Efficacy at 12 Weeks of Treatment

The company gets off to a roaring start in June with an important FDA nod.

BOSTON, June 01, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-savi

The FDA has approved Paratek Pharmaceuticals Inc's (NASDAQ: PRTK) supplemental marketing application for the oral-only dosing regimen of Nuzyra for Community-Acquired Bacterial Pneumonia (CABP). The